Head-To-Head Survey: CVRx (NASDAQ:CVRX) versus Xcorporeal (OTCMKTS:XCRP)

Xcorporeal (OTCMKTS:XCRP) and CVRx (NASDAQ:CVRX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, valuation and profitability.

Profitability

This table compares Xcorporeal and CVRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xcorporeal	N/A	N/A	N/A
CVRx	-89.14%	-120.76%	-48.38%

Earnings & Valuation

This table compares Xcorporeal and CVRx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xcorporeal	N/A	N/A	N/A	N/A	N/A
CVRx	$56.65 million	2.30	-$53.31 million	($2.02)	-2.43

Xcorporeal has higher earnings, but lower revenue than CVRx.

Institutional & Insider Ownership

75.3% of CVRx shares are owned by institutional investors. 13.9% of CVRx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and target prices for Xcorporeal and CVRx, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xcorporeal	0	0	0	0	0.00
CVRx	1	0	1	1	2.67

CVRx has a consensus price target of $11.50, indicating a potential upside of 134.22%. Given CVRx’s stronger consensus rating and higher probable upside, analysts clearly believe CVRx is more favorable than Xcorporeal.

Summary

CVRx beats Xcorporeal on 7 of the 10 factors compared between the two stocks.

About Xcorporeal

Xcorporeal, Inc. is in the process of liquidation and dissolution, pursuant to the plan adopted by board of directors of the company on February 4, 2010. The company has formed the liquidating trust, Xcorporeal, Inc. Liquidating Trust, and transferred all of its assets to the trust for the purpose of completing the liquidation and dissolution of the company. Previously, it operated as a medical device company, which was engaged in the development of an extra-corporeal platform technology to be used in devices to replace the function of various human organs. Xcorporeal, Inc. was founded in 2001 and is based in Lake Forest, California.

About CVRx

CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.